Passive Transfer of Immediate Hypersensitivity and Airway Hyperresponsiveness by Allergen-specific Immunoglobulin (Ig) E and IgG1 in Mice

Akihiro Oshiba, Eckard Hamelmann, Katsuyuki Takeda, Katherine L. Bradley, Joan E. Loader, Gary L. Larsen, and Erwin W. Gelfand

Divisions of Basic Sciences and Pulmonary Medicine, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206

Abstract

In a proportion of atopic asthmatics, exposure to a relevant antigen is followed by chronic inflammation in the airways leading to altered airway responsiveness (AR). However, the mechanisms underlying the development of airway hyperresponsiveness still remain unclear. To elucidate the relationship between IgE-mediated reactions and airway hyperresponsiveness, a murine model of passive sensitization and airway challenge with ovalbumin (OVA) was developed using anti-OVA IgE and IgG antibodies from murine B cell hybridomas. Passive sensitization by intravenous injection of anti-OVA IgE resulted in immediate cutaneous hypersensitivity and, after airway challenge with OVA on two consecutive days, increased AR in BALB/c and SJL mice. Increased numbers of eosinophils were observed in bronchoalveolar lavage fluid, in cells extracted from the lungs, and in the peribronchial areas of BALB/c mice passively sensitized with IgE and challenged through the airways compared with nonsensitized mice. Eosinophil peroxidase activity was also elevated in lung tissue from these mice. Passive sensitization with anti-OVA IgG1 but not IgG2a or IgG3 was similarly associated with development of skin test reactivity and increased AR after airway challenge, accompanied by an increase in eosinophils in bronchoalveolar lavage fluid. These data suggest that IgE/IgG1-mediated reactions together with local challenge with antigen can result in allergic inflammation resulting in altered airway function. (J. Clin. Invest. 1996. 97:1398–1408.) Key words: eosinophils • monoclonal IgE antibody • monoclonal IgG1 antibody • immediate cutaneous hypersensitivity • airway responsiveness

Introduction

It is generally accepted that, in allergic diseases such as asthma, allergen-specific IgE plays a primary role in immediate hypersensitivity reactions, and that such IgE-mediated reactions are followed by chronic inflammation leading to increased airway responsiveness (AR). However, the relationship between immediate hypersensitivity reactions triggered by IgE and subsequent allergic inflammation resulting in airway hyperresponsiveness is not fully defined. Whereas cross-linking of specific IgE bound to mast cells by allergens initially provides specificity to the subsequent sequence of reactions, increasing evidence indicates that T cells, especially T helper type 2 cells, also participate in chronic inflammation. Immunohistochemical studies have shown increased numbers of activated T cells in local inflammatory lesions in allergic diseases (3, 4). After challenge with antigen, increased expression of mRNA encoding T helper type 2–associated cytokines has been demonstrated in sites where allergic inflammation developed (5, 6).

We developed a murine model of allergic sensitization in which BALB/c mice, exposed to an aerosolized antigen, develop antigen-specific IgE, immediate cutaneous hypersensitivity, and increased AR to either intravenous methacholine (7) or electrical field stimulation (8, 9). In most animal models of allergic sensitization, including our approach with aerosolized antigen exposure, altered AR was always accompanied by elevated levels of antigen-specific IgE in the serum (10, 11). However, these observations do not necessarily invoke a causal association between antigen-specific IgE and airway hyperresponsiveness, especially since repeated challenges with antigen are required for these responses. Whether IgE-mediated reactions are necessary or sufficient for the development of airway hyperresponsiveness remains to be determined, as does the definition of the role of antigen-specific T cells recruited to local sites.

Previous investigations have suggested the presence of alternative pathways for triggering immediate hypersensitivity (12). Murine IgG1 is capable of sensitizing murine mast cells, independently of IgE, although IgG subclass antibodies may also interfere with mast cell sensitization to IgE (13, 14). There is a possibility that allergen-specific IgG1, induced in sensitized animals, mediates not only immediate hypersensitivity but also airway hyperresponsiveness.

To define these relationships between allergen-specific IgE-mediated responses and airway hyperresponsiveness further and to explore the ability of IgG subclass antibodies to elicit hypersensitivity responses, we generated murine B cell hybridomas secreting ovalbumin (OVA)-specific IgE and IgG

Address correspondence to Dr. Erwin W. Gelfand, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, 1400 Jackson Street, Denver, CO 80206. Phone: 303-398-1196; FAX: 303-270-2105.

Received for publication 31 August 1995 and accepted in revised form 5 January 1996.


© The American Society for Clinical Investigation, Inc.

0021-9738/96/03/1398/11 $2.00

Volume 97, Number 6, March 1996, 1398–1408

Notes

1. Abbreviations used in this paper: AR, airway responsiveness; BAL, bronchoalveolar lavage; EPO, eosinophil peroxidase; ES<sub>50</sub>, electrical stimulation resulting in 50% maximal contraction; KLH, keyhole limpet hemocyanin; OVA, ovalbumin; PCA, passive cutaneous anaphylaxis; TNP, trinitrophenyl.
We performed passive transfer experiments with these mAbs, monitoring immediate cutaneous reactivity and changes in AR after airway challenge. This approach provides an excellent means for analyzing the effects of allergen-specific IgE or IgG subclass antibodies on both immediate hypersensitivity reactions and airway hyperresponsiveness. In this study, we show that passive sensitization with both OVA-specific IgE and IgG1 causes immediate cutaneous hypersensitivity and played an essential role in the development of airway hyperresponsiveness after specific antigen challenge via the airways.

Methods

Animals. Female BALB/c and SJL/J mice 8–12 wk of age were obtained from The Jackson Laboratory (Bar Harbor, ME). The mice were maintained on OVA-free diets. All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of the National Jewish Center for Immunology and Respiratory Medicine.

Antigens. OVA (grade V; Sigma Chemical Co., St. Louis, MO) was used for immunization and airway challenge. Trinitrophenyl (TNP)–keyhole limpet hemocyanin (KLH) (Boehringer Mannheim Corp., Indianapolis, IN) conjugate was prepared as previously described (15). Total protein concentration of the conjugate and hapten/carryer ratio was determined by spectrophotometric measurement. The product had a molar ratio of 960 TNP/KLH. BSA (grade V; Sigma Chemical Co.) was used as control antigen for skin testing and airway challenge.

Immunization and cell preparation. BALB/c mice were immunized intraperitoneally with 10 μg OVA absorbed on 2.25 mg alum (Imject Alum; Pierce, Rockford, IL) two times over 2 wk. 1 wk after the last immunization, spleens were removed and mononuclear cells were purified by dispersing small tissue pieces through stainless steel mesh followed by density gradient centrifugation (Lymphocyte Separation Medium; Organon Teknika, Durham, NC). The cells were washed three times with PBS and resuspended in RPMI 1640 medium (GIBCO BRL, Gaithersburg, MD).

Generation of anti-OVA antibody-secreting hybridoma cell lines. The aminopterin-sensitive myeloma cell line SP2/0, which produces no Ig chains (American Type Culture Collection [ATCC], Rockville, MD) was grown in RPMI 1640 medium supplemented with 15% heat-inactivated bovine calf serum (HyClone Laboratories, Logan, UT) 5 mM l-glutamine, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from GIBCO BRL). Established hybridomas were cultured in the same medium. All cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2.

Spleen cells from BALB/c mice immunized with OVA were fused with myeloma cells as described previously (16) with some minor modifications. Briefly, 1 × 106 splenic cells were resuspended in 0.1 ml serum-free medium with 3 × 106 myeloma cells; 0.5 ml 50% polyethylene glycol, molecular weight 4,000 (ATCC) in PBS, was added to the cell pellet slowly for 2 min; and then cells were centrifuged for 3 min at 100 g. The polyethylene glycol was diluted with 8 ml serum-free medium, and then bovine calf serum was added to a final concentration of 15%. The cells were placed into a tissue culture dish in the presence of 200 U/ml murine IL-4 (kindly provided by Dr. Paul Trotta, Schering-Plough, Bloomfield, NJ). After 6 h, the cells were diluted and seeded into six 96-well microplates (150 μl/well). 1 d after fusion, 100 μl of selective medium containing 50 μg/ml hypoxanthine and 4 μg/ml azaserine was added to each well. Supernatants of wells with growing hybridoma cells were screened 1–2 wk after cell fusion for anti-OVA IgE and IgG antibodies by ELISA assays as described below. Hybridoma cells secreting anti-OVA antibodies were recloned several times by limiting dilution. OVA-specific subclones from culture plates with cell growth in < 30% of all wells were selected, transferred to a 24-well culture plate, and cultured for 7–10 d; supernatants were harvested and pooled. Hybridoma cell lines producing monoclonal anti-TNP IgE and IgG1 antibodies (ATCC) were also used as a source of specific antibodies.

Measurement of anti-OVA antibody and total Ig levels. Anti-OVA IgE and IgG antibody levels in culture supernatants of hybridomas and serum were assayed by ELISA as previously described (9). The antibody titers of the samples were related to pooled standards that were generated in the laboratory and deliberately assigned to be 100 U/ml. Wells containing supernatants with > 100 U/ml of anti-OVA were selected as positive for screening hybridomas. Total IgE, IgG1, IgG2a, and IgG3 levels were determined using the same method in plates coated with sheep anti-mouse IgE or IgG antibodies (The Binding Site Inc., San Diego, CA) and adding alkaline phosphatase-conjugated rat anti–mouse IgE, IgG1, IgG2a, IgG3 (PharMingen, San Diego, CA), or sheep anti–mouse IgG. Total Ig levels were calculated by comparison with known mouse IgE, IgG, and each IgG subclass standard (PharMingen). The limit of detection was 100 pg/ml for IgE and 1 ng/ml for IgG and each IgG subclass.

Antibody-binding assays as a measure of functional affinity. Direct binding assays were carried out in a microtiter plate coated with OVA as described above in antigen-specific ELISA to determine functional affinities of antibodies secreted by OVA-specific hybridomas. Twofold dilutions of supernatants containing anti-OVA IgE or IgG isotypes were added at concentrations ranging from 15.6 to 2,000 ng/ml. Bound antibodies were detected using alkaline phosphatase-conjugated sheep anti-mouse IgG(Fc) antibody (The Binding Site Inc.), or biotinylated anti–mouse κ chain antibody (kindly provided by Dr. L. Wysocki, National Jewish Center, Denver, CO) and alkaline phosphatase–conjugated avidin (PharMingen). After adding alkaline phosphatase substrate, resulting OD (410 nm) values were determined with an ELISA reader. Antibody concentrations were determined by total Ig ELISA, as described above.

Passive cutaneous anaphylaxis (PCA) reaction. The PCA reaction using culture supernatants was performed with BALB/c mice as described (13). Samples, 30 μl of log dilutions of supernatants, were injected intracutaneously on the shaved abdomen. After 1–2 d, the animals were challenged with an intranasal injection of 0.2 ml of a solution containing 5 mg/ml OVA or TNP-KLH in PBS and 1% Evans blue. After 30 min, the bluing reaction was read. PCA titers are expressed as the log2 of a reciprocal value of the highest dilution providing a PCA reaction.

Passive sensitization with monoclonal anti-OVA antibodies and airway challenge with aerosolized OVA. Mice (three to four mice per group per experiment) were passively sensitized by intravenous injection of a hybridoma supernatant containing anti-OVA antibodies. Groups of mice received an injection on two consecutive days with hybridoma supernatant containing 2 μg anti-OVA IgE, IgG1, IgG2a, or IgG3 in a volume of 200 μl. The original pools of supernatants had a range of Ig concentrations from 10 to 20 μg/ml (as measured by isotype-specific ELISA) and were diluted with PBS to a concentration of 10 μg/ml to standardize each injection of the various mAbs. We established these different hybridoma cell lines secreting OVA-specific IgE. Each anti-OVA IgE hybridoma showed approximately equal titers as determined by ELISA for OVA-specific IgE when adjusted for total IgE content and were equivalent in PCA reactions. Preliminary experiments, in which BALB/c mice received up to five injections of each hybridoma supernatants, showed that at least two injections of 2 μg anti-OVA IgG1 were necessary to obtain positive immediate cutaneous hypersensitivity reactions consistently, while a single injection of 2 μg anti-OVA IgE was sufficient for developing positive skin test responses 7 d later. Age-matched control mice received culture supernatants of the parental myeloma cell line or hybridomas secreting anti-TNP IgE, anti-OVA IgG2a, or anti-OVA IgG3, following the same protocol. The passively sensitized mice were exposed to nebulized OVA (1% wt/vol diluted in PBS) for 20 min daily, 3 and 4 d after the last injection of antibody. This interval between the injections of IgE, airway challenge and monitoring of
AR was determined to be optimal for demonstrating specific changes in airway function. As a positive control group, some mice were actively sensitized with two intraperitoneal injections of OVA plus alum as described above. These mice were also challenged with nebulized OVA 6 and 7 d after the second intraperitoneal injection. 1–2 d after the last airway challenge, skin testing and AR were performed and evaluated by an investigator who was blinded to the sensitization and treatment status of the animals.

Analysis of immediate cutaneous hypersensitivity and systemic anaphylaxis. Development of immediate cutaneous hypersensitivity to OVA in passively sensitized mice was assessed by intradermal skin testing as described previously (9). The abdomen of the mouse was shaved and 20 μl of test solution was injected intradermally with a 30-gauge needle. Test solutions were OVA diluted in PBS at a concentration of 500 μg/ml with PBS as the negative control, and 500 μg/ml of BSA in some experiments. Subsequent wheal reactions were assessed after 15 min and were scored as positive if the wheal diameter was > 5 mm in any direction. The actual size of the wheal response was measured.

Passive sensitization was also performed to induce a systemic anaphylaxis reaction. Mice were challenged by intravenous administration of 500 μg OVA 1 d after completion of passive sensitization as described above. The animals were monitored for development of acute symptoms for up to 20 min.

Determination of AR. Airway smooth muscle responsiveness was determined in vitro as described (17). Briefly, after killing the animals, mouse tracheal rings of ∼ 0.5 cm in length were sectioned and placed in Krebs-Henseleit baths suspended by triangular supports transducing the force of contractions. Electrical field stimulation was delivered by an S44 stimulator (SIV 5; Grass Instrument Co., Quincy, MA) using 8 V, 2-ms pulse duration, and 0.5–40-Hz frequencies. Each stimulation was maintained until peak contractile responses were obtained. The 40-Hz frequency was established earlier to result in maximal contractions. ESO, the frequency that caused 50% of maximal contractions, was calculated from linear plots.

Bronchoalveolar lavage (BAL). BAL fluid was obtained and lung perfusion was performed 1 d after the last exposure to aerosolized OVA. Immediately after killing the animals, the tracheas were intubated with a polyethylene catheter and the lungs were lavaged with 3 ml HBSS. The total number of cells from the recovered BAL fluid was counted with a hemocytometer. Approximately 2.4–2.7 ml of fluid was recovered from each animal. For differential cell counts, slides were prepared with a cytospin (Shandon Scientific, Pittsburgh, PA) and cells were stained with Wright stain (Leukostat; Fisher Diagnostics, Pittsburgh, PA). Aliquots of the BAL fluid were centrifuged and the supernatants were collected and stored at −20°C for measurement of eosinophil peroxidase (EPO) activity.

Preparation of cells from lung tissue. Lung cells were isolated as previously described (18). After performing BAL with 3 ml of HBSS, lungs were perfused with warmed (37°C) calcium- and magnesium-free HBSS containing 10% FCS, 0.6 mM EDTA, 100 U/ml penicillin, and 100 μg/ml streptomycin via the right ventricle at a rate of 4 ml/min for 4 min. Lungs were removed, cut, and minced through a 300-μm-wide tissue grid. 4 ml of HBSS containing 175 U/ml collagenase (type IA; Sigma Chemical Co.), 10% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin were added to the minced lungs and incubated for 60 min in an orbital shaker at 37°C. The digested lungs were sheared with a sterile 20-gauge needle and filtered through 45-μm and 15-μm filters. Filters were washed with HBSS/2% FCS (45 μm, 1 × 5 ml; 15 μm, 2 × 10 ml). Cells were resuspended in HBSS and counted with a hemocytometer, and cytospin slides were made. Slides were stained with Leukostat and cell differentiation percentages were determined, counting at least 200 cells using a light microscope. Remaining cells were pelleted and resuspended in 1% NP-40 (Sigma Chemical Co.) in distilled water at 2 × 10⁶ cells/ml, and samples stored at −20°C for measurement of EPO activity.

Lung histology and eosinophil counts. For histologic examination, lung perfusion was performed as described above and 1–2 ml of formalin fixing solution was instilled intratracheally after BAL. The lungs were then removed and fixed in formalin solution. One lobe of the lung was embedded in paraffin, and sections of 5-μm thickness were prepared and stained with astra blue and vital new red for staining eosinophil granules as previously described (19). Histologic evaluation of the peribronchial regions of the lung was performed by light microscopy, and tissue slides were examined by an observer in a blind fashion. The number of eosinophils around the bronchi (mucosal and submucosal areas) was counted at a magnification of 400. Counts were performed using a minimum of ten randomly selected bronchial cross-sections of medium size and expressed per millimeter squared using a computer-assisted graphics program (IP Lab Spectrum; Signal Analytics Co., Vienna, VA).

Determination of EPO activity. Levels of EPO in BAL fluid and the cells extracted from the lungs were determined as previously described (20). Briefly, 100 μl of the substrate solution (0.1 mM o-phenylene-diamine-dihydrochloride, 0.1% Triton X-100, 1 mM hydrogen peroxide in 0.05 M Tris-HCl; all reagents from Sigma Chemical Co.) was added to 100 μl of sample in microtiter plates and incubated for 30 min at 37°C. The reaction was stopped by adding 50 μl of 4 M sulfuric acid, and the optical densities were read in a microtiter autoreader at 492 nm. This method has been demonstrated to be specific for eosinophil, since, when using o-phenylene-diamine-dihydrochloride as the hydrogen donor, neutrophils show no significant activity (20).

Statistical analysis. A multiple comparison analysis of levels of differences between experimental groups and control conditions was performed using a Dunnett’s or Tukey-Kramer HSD test. Values for all measurements are expressed as the mean ± SD except values for ESO, which are presented as the mean ± SEM.

Results

Functional affinities of isotypes secreted by anti-OVA–specific hybridoma clones. Direct immunoassay for antigen-specific antibody has been described using antigen-coupled microtiter plates (21). A variation of this procedure by ELISA was used to measure relative functional affinities of OVA-specific mAbs. Antigen-specific binding for eight anti-OVA IgG hybridoma supernatants was detected by anti-mouse IgG (Fc) antibody (Fig. 1 A), and the concentration responsible for 50% maximal binding was calculated to compare functional affinities among the different isotypes. Since previous studies demonstrated that functional affinities determined by antibody-binding immunoassay are correlated with affinities (Kd) determined by fluorescence quenching (21), one supernatant showing the lowest 50% binding point was selected for each isotype for passive sensitization (IgG isotype numbers 1, 4, and 6). The antigen-specific binding was compared between these anti-OVA IgG antibodies and anti-OVA IgE (number 8), which were selected for passive sensitization, using anti-mouse κ chain antibody (Fig. 1 B). Monoclonal anti-OVA antibodies screened in preliminary experiments were shown to bear κ light chain. The isotypes chosen for passive sensitization demonstrated relatively equal affinity. None of the isotypes showed significant binding to BSA-coated plates (data not shown).

PCA reaction. The ability of monoclonal anti-OVA antibodies to sensitize mouse skin tissue for antigen-induced immediate hypersensitivity responses was tested by PCA reactions. Serial dilutions (PBS) of hybridoma culture supernatants starting at a concentration of 10 μg/ml of each isotype were used. Both IgE and IgG1 antibodies demonstrated skin-sensitizing capacity (Table I). The PCA titers of the IgE antibody specific for OVA and TNP were higher than the IgG1 anti-
Passive Sensitization by Antigen-specific IgE and IgG1

body with similar specificity (despite slightly higher affinity), but differences were not significant. The PCA reactions were shown to be antigen specific by using an irrelevant antigen. IgG2a and IgG3 antibodies specific for OVA failed to produce a positive PCA reaction, even using concentrations up to 10−20 μg/ml (data not shown).

**OVA-specific antibody and total Ig levels in serum of passively sensitized mice.** Serum OVA-specific antibody and total Ig levels were analyzed in mice receiving passive sensitization or active intraperitoneal immunization 1 d after completion of the nebulization protocol. Whereas anti-OVA IgE, IgG1, and IgG antibody levels were elevated in the serum of intraperitoneally immunized mice, OVA-specific IgE or IgG1 levels were significantly higher in mice passively sensitized with supernatants containing the corresponding isotype (subclass) than the intraperitoneally immunized mice (Table II). Mice passively sensitized with anti-OVA IgE showed significantly higher total IgE serum levels than intraperitoneally immunized mice, and no significant differences were observed in total IgG levels among the different treatment groups. Challenge with OVA alone via the airways on two occasions did not affect total IgG or IgE levels, nor did it result in detectable OVA-specific antibodies.

Passively sensitized mice develop antigen-induced immediate cutaneous reactivity and systemic anaphylaxis. As described previously (8, 9), sensitization of BALB/c mice to aerosolized antigens such as ragweed and ovalbumin via the airways led to the induction of immediate cutaneous hypersensitivity associated with antigen-specific IgE and IgG production. We deter-

### Table I. PCA Reactions Using Supernatants from Anti-OVA-secreting Hybridomas

<table>
<thead>
<tr>
<th>Supernatant</th>
<th>Antigen</th>
<th>PCA titer</th>
</tr>
</thead>
<tbody>
<tr>
<td>OVA-IgE</td>
<td>OVA</td>
<td>9.3±0.5</td>
</tr>
<tr>
<td>OVA-IgE</td>
<td>TNP-KLH</td>
<td>0</td>
</tr>
<tr>
<td>OVA-IgG1</td>
<td>OVA</td>
<td>8.3±0.5</td>
</tr>
<tr>
<td>OVA-IgG1</td>
<td>TNP-KLH</td>
<td>0</td>
</tr>
<tr>
<td>TNP-IgE</td>
<td>TNP-KLH</td>
<td>9.0±0.8</td>
</tr>
<tr>
<td>TNP-IgE</td>
<td>OVA</td>
<td>0</td>
</tr>
<tr>
<td>TNP-IgG1</td>
<td>TNP-KLH</td>
<td>7.0±0.8</td>
</tr>
<tr>
<td>TNP-IgG1</td>
<td>OVA</td>
<td>0</td>
</tr>
</tbody>
</table>

PCA titers of supernatants containing IgE and IgG1 antibodies specific for OVA and TNP were determined. Mice receiving intradermal injections with serial dilutions of supernatants were challenged with an intravenous injection of a solution containing specific or irrelevant antigen and Evans blue. PCA titers are expressed as the log of the reciprocal value of the highest dilution providing a positive PCA reaction. Presented are the means±SD of four mice.

### Table II. OVA-specific Antibody and Total Ig Levels in the Serum

<table>
<thead>
<tr>
<th>Sensitization</th>
<th>OVA-specific antibody levels</th>
<th>Total Ig levels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IgE</td>
<td>IgG1</td>
</tr>
<tr>
<td>None</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>OVA-IgE</td>
<td>*169±33</td>
<td>&lt;1</td>
</tr>
<tr>
<td>OVA-IgG1</td>
<td>&lt;1</td>
<td>314±78</td>
</tr>
<tr>
<td>OVA/alum</td>
<td>*82±13</td>
<td>*65±16</td>
</tr>
</tbody>
</table>

Serum titers for OVA-specific antibodies and total Ig were determined by ELISA in mice actively or passively sensitized: nonsensitized control mice (n = 8), mice passively sensitized with anti-OVA IgE (OVA-IgE, n = 8) or anti-OVA IgG1 (OVA-IgG1, n = 6), or mice immunized with OVA/alum (OVA/alum, n = 4). Presented are the means±SD.

*Significant (P < 0.05) differences between the groups.

Passive Sensitization by Antigen-specific IgE and IgG1 1401
Table III. OVA-specific Immediate Cutaneous Hypersensitivity

<table>
<thead>
<tr>
<th>Sensitization</th>
<th>Nebulization</th>
<th>Mean wheal diameter±SD</th>
<th>Number of positive responders (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. BALB/c mice</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>1.9±0.3</td>
<td>0/8 (0)</td>
</tr>
<tr>
<td>None</td>
<td>OVA×2</td>
<td>3.1±0.5</td>
<td>0/8 (0)</td>
</tr>
<tr>
<td>SP2/0</td>
<td>OVA×2</td>
<td>3.4±0.4</td>
<td>0/15 (0)</td>
</tr>
<tr>
<td>TNP-IgE</td>
<td>OVA×2</td>
<td>4.2±0.5</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>OVA-IgE</td>
<td>OVA×2</td>
<td>*16.8±0.8</td>
<td>6/6 (100)</td>
</tr>
<tr>
<td>OVA-IgG1</td>
<td>OVA×2</td>
<td>*15.9±0.9</td>
<td>15/15 (100)</td>
</tr>
<tr>
<td>OVA-IgG2a</td>
<td>OVA×2</td>
<td>*15.1±1.2</td>
<td>10/10 (100)</td>
</tr>
<tr>
<td>OVA-IgG3</td>
<td>OVA×2</td>
<td>3.7±0.7</td>
<td>0/8 (0)</td>
</tr>
<tr>
<td>OVA-IgE</td>
<td>OVA×2</td>
<td>4.0±0.5</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>OVA/alum</td>
<td>OVA×2</td>
<td>*15.8±1.0</td>
<td>8/8 (100)</td>
</tr>
</tbody>
</table>

B. SJL mice

|            | OVA×2        | *13.9±1.1              | 11/11 (100)                       |

A decrease in the ES50 represents an increase in AR (17). Nonsensitized control BALB/c mice had a mean (±SEM) ES50 of 4.0±0.2 Hz. In mice passively sensitized with anti-OVA IgE supernatants, airway challenge with OVA on two consecutive days resulted in a significant decrease in the ES50 levels to 2.0±0.2 Hz (P < 0.001). Injection of IgE in the absence of airway challenge resulted in no significant changes in AR. A single challenge with aerosolized antigen was insufficient to develop airway hyperresponsiveness after passive sensitization with anti-OVA IgE, and two challenges with nebulized OVA alone caused no significant changes in AR (Fig. 2). To test the specificity of the IgE-mediated effect on AR, control culture supernatants from the parental myeloma cell line were administered before OVA challenge. To compare the effects of passive sensitization with specific antibodies on AR among the different groups. A decrease in the ES50 represents an increase in AR (17). Nonsensitized control BALB/c mice had a mean (±SEM) ES50 of 4.0±0.2 Hz. In mice passively sensitized with anti-OVA IgE supernatants, airway challenge with OVA on two consecutive days resulted in a significant decrease in the ES50 levels to 2.0±0.2 Hz (P < 0.001). This was similar to the response in mice actively immunized (OVA/alum) and challenged via the airways (2.3±0.2 Hz) (Fig. 2). Injection of IgE in the absence of airway challenge resulted in no significant changes in AR. A single challenge with aerosolized antigen was insufficient to develop airway hyperresponsiveness after passive sensitization with anti-OVA IgE, and two challenges with nebulized OVA alone caused no significant changes in AR (Fig. 2). To test the specificity of the IgE-mediated effect on AR, control culture supernatants from the parental myeloma cell line were administered before OVA challenge. To compare the effects of passive sensitization with specific antibodies on AR among the different groups. A decrease in the ES50 represents an increase in AR (17). Nonsensitized control BALB/c mice had a mean (±SEM) ES50 of 4.0±0.2 Hz. In mice passively sensitized with anti-OVA IgE supernatants, airway challenge with OVA on two consecutive days resulted in a significant decrease in the ES50 levels to 2.0±0.2 Hz (P < 0.001). The same acute reactions were observed in mice sensitized with anti-OVA IgG1 (4/4 fatal). None of the mice receiving injections of anti-TNP IgE or IgG1 displayed any symptoms after OVA challenge.

Figure 2. Passive sensitization with specific IgE causes airway hyperresponsiveness after antigen challenge via the airways. AR was analyzed in several groups of mice injected with control supernatant from the parental myeloma cell line (SP2/0), mice passively sensitized with TNP-specific IgE (TNP-IgE) or OVA-specific IgE (OVA-IgE), or mice actively immunized with OVA/alum (intraperitoneal OVA), followed by airway challenge with nebulized antigen on 1 d (OVA ×1) or on two consecutive days (OVA ×2 or BSA ×2). AR was analyzed 2 d after completion of airway challenge by electrical field stimulation of tracheal smooth muscle preparations. AR is expressed as a percentage of control ES50. The mean (±SEM) ES50 for nonsensitized control animals (n = 22) was 4.0±0.2 Hz, and this value was taken as 100%. Presented are the means±SEM for each group from independent experiments using three to four mice in each group in each experiment. *Significant differences compared with nonsensitized controls (P < 0.01) and all other experimental groups (P < 0.05). ns, not significant.
challenge, and intravenous injection of IgE antibodies was combined with airway challenge with an irrelevant antigen (BSA). Mice passively sensitized with OVA-specific IgE developed airway hyperresponsiveness only when followed by airway exposure to the corresponding antigen, demonstrating the specificity of IgE-induced responses in the airways (Fig. 2).

The ability of anti-OVA IgG antibodies to alter AR was evaluated after exposure to nebulized OVA. Only mice passively sensitized by two injections of anti-OVA IgG1 antibody but not IgG2a or IgG3 antibodies (even after five injections) resulted in an increase in AR after airway challenge (Fig. 3).

SJL/J mice were passively sensitized with monoclonal IgE antibodies and challenged with antigen via the airways. Mice passively sensitized with anti-OVA IgE also developed airway hyperresponsiveness after airway exposure to OVA to a degree comparable to that of BALB/c mice sensitized and challenged in the same way (Fig. 4).

Effect of passive sensitization on cell composition in BAL fluid after airway challenge. Total leukocyte counts and differential cell counts in BAL fluid of individual mice were assessed in passively or actively sensitized mice. The numbers of total leukocytes and macrophages recovered from BAL were significantly higher in passively and actively immunized mice after two airway challenges compared with nonsensitized mice (airway challenge alone) (Fig. 5). Lymphocytes and neutrophils were significantly increased in the mice actively (intraperitoneally) immunized but not in passively sensitized animals. In the groups passively sensitized with specific IgE or IgG1, statistically larger numbers of eosinophils were observed compared with the nonsensitized group in which no eosinophils were detected. The intraperitoneally immunized group showed a larger number of eosinophils than the passively sensitized groups. The group receiving injections of anti-TNP IgE showed no difference in absolute counts for leukocytes in BAL from the nonsensitized controls. Passive sensitization alone or together with a single challenge, or active immunization alone, did not affect the leukocyte counts (data not shown).

Figure 3. Passive sensitization with specific IgG1 but not IgG2a and IgG3 causes airway hyperresponsiveness after antigen challenge via the airways. Groups of mice were passively sensitized with OVA-specific IgG1, IgG2a, or IgG3 antibody (OVA-IgG1, OVA-IgG2a, or OVA-IgG3, respectively) and challenged with nebulized OVA on two consecutive days. AR was expressed as a percentage of control ES50 and compared with the value for the mice passively sensitized with anti-OVA IgE as described in Fig. 1. Presented are the means±SEM for each group from independent experiments using three to four mice in each group in each experiment. *Significant differences (*P < 0.001 and †P < 0.005) compared with nonsensitized control mice. ‡Significant differences between the groups (P < 0.05).

Figure 4. SJL mice passively sensitized with specific IgE develop airway hyperresponsiveness after airway challenge. SJL mice were passively sensitized with TNP-specific IgE (TNP-IgE) or OVA-specific IgE (OVA-IgE) and exposed to nebulized OVA on two consecutive days. AR was expressed as a percentage of control ES50. The mean (±SEM) ES50 for nonsensitized control animals (n = 12) was 4.9±0.6 Hz, and this value was taken as 100%. Presented are the means±SEM for each group from independent experiments using three to four mice in each group in each experiment. *P < 0.01 compared with nonsensitized control. ‡Significant difference between the groups (P < 0.05).

Effect of passive sensitization on composition of lung cells after airway challenge. Total leukocyte counts and differential counts for cells retrieved from lung tissue of individual mice were compared for nonsensitized and actively sensitized mice after airway challenge. There were no differences in total leukocyte counts among the groups (Fig. 6). The absolute numbers of macrophages/monocytes were lower in both sensitized groups compared with nonsensitized mice. The lymphocyte numbers were increased in the passively sensitized group, and neutrophil numbers were increased in the actively immunized group. Significant numbers of eosinophils were detected in both of the sensitized groups compared with the controls. Passive sensitization alone
or together with a single challenge did not affect the leukocyte counts (data not shown).

Effect of passive sensitization on eosinophil counts in lung sections after airway challenge. Histological examination was performed 1 d after the last airway challenge with OVA, and eosinophil counts in peribronchial regions were assessed in nonsensitized and in passively (with anti-OVA IgE) sensitized mice after airway challenge. In passively sensitized mice receiving two airway exposures to OVA, multifocal infiltrates of inflammatory cells were observed predominantly in the submucosa of bronchi (and bronchioli). Passively sensitized mice demonstrated significantly higher numbers of eosinophils in the peribronchial areas compared with nonsensitized mice after two airway challenges (Fig. 7). In mice receiving passive sensitization with specific IgE, a significant increase in eosinophil numbers. Passive sensitization alone had no effect on eosinophil counts in the lung tissue.

Effect of passive sensitization on EPO levels in supernatants of BAL fluid and lung cells. EPO activities in the supernatants of BAL fluid and the lysed pellets of cells isolated from lung tissue were determined in nonsensitized or sensitized mice after antigen challenge via the airways. Active immunization (OVA/alum) and airway challenge resulted in a significant increase in EPO levels in the supernatants of BAL fluid and in the pellets of cells isolated from lung tissue (Fig. 7). In the group receiving passive sensitization with specific IgE, a significant increase in EPO activity was observed in the pellets of lung cells but not in BAL fluid.

Discussion

The relationship between IgE-mediated mast cell activation, eosinophil accumulation, and T cell recruitment in chronic inflammation of the airways is not well defined. In previous studies, we demonstrated in BALB/c mice that repeated exposure to antigenic proteins such as OVA or ragweed induced an antigen-specific IgE response and emphasized that different T cell populations from sensitized mice play regulatory roles in IgE production (7, 8). In each case, the IgE response was consistently associated with the acquisition of immediate cutaneous hypersensitivity (9) and the development of increased AR (17). In contrast, in SJL/J mice, where the mice failed to gener-
Passive Sensitization by Antigen-specific IgE and IgG1

in this way obviated the need for repeated antigen exposure via the airways to generate an IgE response, which prevented critical analysis of the components contributing to the alterations in AR. Passive sensitization with anti-OVA IgE predictably resulted in immediate wheal responses to intradermal injection of antigen and positive PCA reactions. In the absence of airway challenge with the relevant (concordant) antigen, passive sensitization with IgE was insufficient to elicit airway changes. This confirmed previous studies in SJL mice (17) and in BALB/c mice sensitized to OVA via the skin to elicit an IgE response but no altered AR (23). In fact, two exposures to OVA via the airways was required after passive sensitization with IgE anti-OVA antibody to trigger alterations in AR. The response was specific in that IgE anti-TNP antibody coupled with OVA exposure was not effective, nor was airway exposure alone on two occasions in the absence of passive sensitization. In previous reports using animal models of antigen-induced airway hyperreactivity, increases in eosinophils were demonstrated in both BAL fluid and lung cells recovered from lung digestion and correlated with increased AR (24–26). Passively sensitized and challenged mice also demonstrated increased numbers of eosinophils in the peribronchial regions and increased EPO levels in the lung tissue, indicating that the combination of passive sensitization with IgE and limited airway exposure to antigen is sufficient to elicit inflammatory changes coupled with development of airway hyperresponsiveness. These increases in AR as measured by electrical field stimulation in allergen-sensitized mice after airway challenge have been shown to correlate with an increase in acetylcholine release from neural terminals, presumably based on altered neural control of airways and/or dysfunction of the M2 muscarinic autoreceptor (27).

The extent of these changes after passive sensitization were similar to what we observed in animals actively immunized (intraperitoneally) with the combination of OVA/alum before airway challenge. In both cases, increased numbers of macrophages were detected in BAL fluid from sensitized mice, whereas lower numbers were demonstrated in lung tissue. The

Figure 7. Eosinophil counts in peribronchial regions. Numbers of eosinophils observed in the peribronchial areas in the lung sections were determined in the following groups of mice: nonsensitized mice receiving two airway challenges with OVA (None) or mice passively sensitized with anti-OVA IgE (OVA-IgE) and receiving one or two airway challenges with OVA. Presented are the means±SD of four mice from two independent experiments in each group. *P < 0.05 compared with nonsensitized control mice.

Figure 8. EPO levels in supernatants of BAL fluid and pellets of lung cells. EPO activity was measured in the supernatants of BAL fluid (A) and the lysed pellets of lung cells (B) in samples obtained from the same groups of mice described in Fig. 5. Presented are the means±SD. *Significant differences (*P < 0.05 and †P < 0.01) compared with nonsensitized control mice.
major differences were that, although actively immunized mice demonstrated lower IgE levels, significantly higher neutrophil and eosinophil numbers were demonstrated in lung tissue and BAL fluid. Changes in AR were similar. One possible explanation for the discordance between levels of increased AR and eosinophil numbers observed in passively and actively sensitized mice is that the degree of eosinophil accumulation may not parallel the development of airway hyperresponsiveness. Previous studies showed that eosinophil activation rather than accumulation in local tissue is correlated to increased AR (28), whereas, in our study, eosinophil activation in the lung tissue as measured by EPO activities appeared to be associated with the development of airway hyperresponsiveness. The failure of IgE levels to correlate directly with eosinophil numbers suggests that additional factors influence eosinophil recruitment to the lung and airways. The greater eosinophil recruitment in actively immunized animals after airway challenge compared with passively sensitized mice could be explained by the degree of activation of antigen-specific T cells. Activated T cells are thought to contribute to the inflammatory response, releasing cytokines that mediate eosinophil recruitment and activation. The finding that neither passive sensitization alone nor two challenges with the relevant antigen alone were sufficient to induce airway hyperresponsiveness may relate to whether limited airway challenges can trigger the activation of antigen-specific T cells in the absence of passive sensitization. Peribronchial lymph node and spleen cells from actively immunized mice proliferated in response to OVA in a dose-dependent manner, as we previously showed (7). A single airway challenge with antigen combined with passive transfer of IgE failed to induce an eosinophil response in the lung or BAL or alteration in AR. Peribronchial lymph node and spleen cells from mice passively sensitized with anti-OVA antibodies and challenged on one occasion showed no significant proliferative responses to OVA 2 d after OVA challenge via the airway. It is possible that limited local exposure to antigen does indeed induce the recruitment and activation of antigen-specific T cells, but they are not detectable in proliferative assays. Passive sensitization combined with two or more challenges with OVA was shown to induce an antigen-specific proliferative response (three- to fivefold over baseline response) in peribronchial lymph node cells. These data suggest that antigen exposure via the airways on two consecutive days alone could be insufficient to expand specific T cells and that the combination of IgE with antigen could augment the responses mediated by antigen-specific T cells.

At present it is not entirely clear how IgE (or IgG1) may result in the heightened antigen-specific T cell responses. B cells or other antigen-presenting cells (e.g., dendritic cells) may bind antigen via specific antibody interactions with Fc receptors expressed on the surface of these cells. In this way, such cells demonstrate a high capacity for antigen presentation of the relevant antigen (29, 30). Cells expressing IgE receptors, FceRI or FceRII, have shown IgE-dependent targeting of allergens to antigen-presenting cells with enhancement of antigen-specific T cell responses (31, 32). In addition to enhancing T cell responsiveness, IgE (or IgG1) antibodies have been shown to enhance the recruitment of effector T cells to the site of local challenge with specific antigen (33).

The role of IgE in mediating allergic inflammation may be at several additional levels. The capability of IgE-mediated mast cell activation to induce allergic inflammation directly is supported by the observation that intradermal administration of anti-IgE antibody can induce late-phase reactions as well as immediate cutaneous reactions (34). It has been reported that mast cells release cytokines such as TNF-α, IL-3, and IL-4 (35–37). These cytokines could activate and recruit eosinophils to the airways. Another possibility is that FceRs are involved in regulating allergic inflammation, especially the low-affinity FceR (FceRII/CD23). These receptors have been demonstrated on various types of cells that can participate in allergic responses (1, 38). Interactions between antigen and IgE passively transferred and bound to FceRII on these effector cells could play a substantial role in allergic inflammation. Recent studies have demonstrated release of EPO from purified eosinophils from patients with parasitic infection or an allergic disease (39). Activation of a respiratory burst in neutrophils incubated with IgE after addition of anti-IgE antibody has also been observed, suggesting that cross-linking of antigen-specific IgE bound to receptors on the cell surface could activate these cells (40).

These results defining a role for IgE in altered AR both support and conflict with data using other approaches from other laboratories. In rats passively sensitized with IgE, acute bronchoconstriction and increased vascular permeability have been observed in the airways after antigen challenge (41, 42). We also observed dyspnea and fatal anaphylactic reactions in mice passively sensitized with anti-OVA IgE and challenged with OVA intravenously. In other studies using rats (42), passive sensitization with IgE anti-DNP antibody resulted in no increases in resistance or inflammation when challenged with antigen via the airways; this contrasted with rats actively immunized with OVA/alum where airway challenge resulted in increases in resistance. In rabbits, infusion of antigen-specific rabbit homocytotropic (IgE) antibody also resulted in late-phase reaction after airway challenge (11).

SJL/J mice passively sensitized with IgE also developed immediate hypersensitivity responses and increased AR. This strain is known to be a low IgE responder because of diminished capacity for IL-4 synthesis (22). Bypassing this deficiency (passive sensitization) resulted in the full ability of these mice to develop alterations in AR and in inflammatory changes similar to those of the BALB/c mice. This implies that, although deficient in Vg8 T cells (the primary expanded population in response to OVA in BALB/c mice [43]) and capable of only limited IL-4 production, these mice can develop allergic inflammatory changes and, as a consequence, altered AR, when given specific IgE antibody.

This is the first demonstration that antigen-specific IgG1 antibodies are not only capable of causing immediate hypersensitivity but are also effective in inducing airway hyperresponsiveness. As described above, IgG1, similar to IgE, can enhance T cell responsiveness and recruit effector T cells to the site of local antigen challenge in mice. Mouse IgG1 can mediate both in vivo PCA reactions and in vitro mast cell sensitization (13, 44). The observation (12) that IgE-deficient mice immunized with OVA still develop systemic anaphylaxis reactions after intravenous antigen challenge suggests the presence of alternative pathways of immediate hypersensitivity, and that IgG1 is one of the candidates that mediates systemic allergic reactions. At present, there is no known analogue of murine IgG1, and whether a second Ig isotype (in addition to IgE) can mediate such changes in airway responsiveness in humans is unknown at present. Conventional sensi-

Passive Sensitization by Antigen-specific IgE and IgG1


